GlobeNewswire

Washington's Road User Charge Goes Live

Dela

ISSY LES MOULINEAUX, France, March 12, 2018 (GLOBE NEWSWIRE) -- emovis, the mobility solution provider of the world's leading highway management firm, Abertis, is thrilled to announce the start of the Washington Road User Charge (WARUC) Pilot Project. 

For 12 months, 2,000 volunteers will participate in the pilot in order to experience the replacement of the gas tax by a pay-per-mile travelled charge. Drivers will simulate paying for the miles they drive rather than the gallons of fuel they buy. The results of this year-long trial will help shape the state's future transportation funding policy.

emovis is proud to take part in this initiative that seeks to explore new ways of providing sustainable transportation revenues to maintain critical road infrastructures in the US. This exciting project illustrates emovis' long history of Road Usage Charge projects in the US, where the company is involved in Oregon's RUC Pilot (wwww.myorego.org) as well as similar projects in Europe. emovis is committed to continuous innovation in conceiving smart road-based mobility solutions.

Cloud-based Mobility Solution 
In addition to implementing a cloud-hosted back office solution, emovis provides On-Board Diagnostic (OBD-II) mileage recording devices and smartphone app technology, thanks to its partnership with Automatic®.

Automatic® is a San Francisco based leader in connecting every car on the road to the internet and empowering drivers with knowledge about themselves and their cars. Through this strategic partnership, emovis is leading the way in introducing a commercially available off-the-shelf consumer product and applying it to a road user charge solution.

The Challenge of Out of State Drivers 
As with any state-based road charging program, out-of-state drivers pose a challenge in terms of compliance and revenue enforcement for state road authorities.

One of the key objectives of WARUC is precisely this-to test multi-jurisdictional charging by relying on the location-aware capabilities of the on-board mileage recording devices. The simulated charges applied to the participants' trips differ depending on the location of each recorded mile travelled. All of this is achieved while adhering to strict privacy and data protection guidelines set out by the State.

About WARUC (www.waroadusagecharge.org)
Washington state is testing a Road Usage Charge (WARUC) where drivers simulate paying for miles driven rather than gallons of gas purchased. Various methods of mileage reporting will be tested during this trial. 

This pilot is aimed at exploring new ways to fund the upkeep of roads as states are confronted with fast declining gas tax-based revenues.

In September 2017, following a competitive tender, emovis was selected to provide a turnkey RUC solution in support of the Washington State Transportation Commission's RUC pilot project.

About emovis 
emovis is focused on keeping roads moving through toll-based smart mobility solutions. With over 600 employees worldwide, the company operates some of the world's largest free-flow tolling infrastructure in the UK, Ireland, U.S., and Canada. 

In addition to being awarded the WA RUC project in 2017, emovis successfully launched UK's second All Electronic Tolling near Liverpool (www.merseyflw.co.uk) last October. The company is 100% owned by Abertis (www.abertis.com), the international market leader in the management of toll roads, managing over 5,300 miles (8,600 kilometres) of high capacity and quality roads in 15 countries in Europe, the Americas and Asia.

www.emovis.com
Media Contact: Benoît ROSSI
communication@emovis.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a36cf3b5-7286-4328-9c6c-4da005563877




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: emovis via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum